HLN Stock Overview
Engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Haleon plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£9.71 |
| 52 Week High | UK£10.80 |
| 52 Week Low | UK£7.89 |
| Beta | 0.24 |
| 1 Month Change | 2.97% |
| 3 Month Change | -7.17% |
| 1 Year Change | 20.02% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 29.47% |
Recent News & Updates
Haleon: Guidance Implies Uncertainty Around Flu Season
Dec 10Haleon: Tailwinds Are Mostly Priced In
Oct 24Recent updates
Haleon: Guidance Implies Uncertainty Around Flu Season
Dec 10Haleon: Tailwinds Are Mostly Priced In
Oct 24Haleon: Defensive Consumer Healthcare Stock As Safe Haven
Aug 06The Investment Case For Haleon: Steady Shareholder Value Accumulation
Nov 20The Share Price Has The Flu, But Haleon Is As Healthy As An Ox
Sep 07Haleon: A Hidden Gem In The Consumer Health Market
Jun 12Haleon exploring sale of ChapStick Brand - report
Feb 25Haleon said to evaluate potential deals to increase its size - report
Jan 31Haleon: Undervalued With Clear Catalyst Ahead
Aug 31Former GSK consumer health unit Haleon hits all-time low
Aug 19Haleon CEO says brand recognition, gross margins will drive growth - CNBC
Jul 20Shareholder Returns
| HLN | US Personal Products | US Market | |
|---|---|---|---|
| 7D | -0.6% | -5.5% | -4.0% |
| 1Y | 20.0% | -24.4% | 24.0% |
Return vs Industry: HLN exceeded the US Personal Products industry which returned -23.8% over the past year.
Return vs Market: HLN underperformed the US Market which returned 26.1% over the past year.
Price Volatility
| HLN volatility | |
|---|---|
| HLN Average Weekly Movement | 2.2% |
| Personal Products Industry Average Movement | 8.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: HLN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: HLN's weekly volatility (2%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1715 | 25,408 | Brian McNamara | www.haleon.com |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues.
Haleon plc Fundamentals Summary
| HLN fundamental statistics | |
|---|---|
| Market cap | US$43.71b |
| Earnings (TTM) | US$1.52b |
| Revenue (TTM) | US$14.14b |
28.8x
P/E Ratio3.1x
P/S RatioIs HLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HLN income statement (TTM) | |
|---|---|
| Revenue | UK£11.24b |
| Cost of Revenue | UK£4.25b |
| Gross Profit | UK£6.99b |
| Other Expenses | UK£5.78b |
| Earnings | UK£1.21b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 27, 2025
| Earnings per share (EPS) | 0.13 |
| Gross Margin | 62.20% |
| Net Profit Margin | 10.75% |
| Debt/Equity Ratio | 54.2% |
How did HLN perform over the long term?
See historical performance and comparisonDividends
1.6%
Current Dividend Yield47%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 14:21 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Haleon plc is covered by 25 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Iain Simpson | Barclays |
| Warren Ackerman | Barclays |
| Bethan Davies | Berenberg |